151 related articles for article (PubMed ID: 35803041)
1. Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysis.
Frost N; Roeper J; Velthaus JL; Raspe M; Olive E; Schmittel A; Schmidt B; Wasilewski D; Onken J; Lüders H; Witzenrath M; Senger C; Böhmer D; Loges S; Griesinger F; Modest DP; Grohé C
Lung Cancer; 2022 Aug; 170():165-175. PubMed ID: 35803041
[TBL] [Abstract][Full Text] [Related]
2. Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
Frost N; Tessmer A; Schmittel A; van Laak V; Raspe M; Ruwwe-Glösenkamp C; Brunn M; Senger C; Böhmer D; Ochsenreither S; Temmesfeld-Wollbrück B; Furth C; Schmidt B; Neudecker J; Rückert JC; Suttorp N; Witzenrath M; Grohé C
Lung Cancer; 2018 Nov; 125():164-173. PubMed ID: 30429016
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
4. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
[TBL] [Abstract][Full Text] [Related]
5. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
6. Proposing synchronous oligometastatic non-small-cell lung cancer based on progression after first-line systemic therapy.
Miyawaki T; Wakuda K; Kenmotsu H; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ono A; Naito T; Murakami H; Notsu A; Mori K; Harada H; Endo M; Ohde Y; Takahashi K; Takahashi T
Cancer Sci; 2021 Jan; 112(1):359-368. PubMed ID: 33098119
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
Miyawaki T; Kenmotsu H; Harada H; Ohde Y; Chiba Y; Haratani K; Okimoto T; Sakamoto T; Wakuda K; Ito K; Uemura T; Sakata S; Kogure Y; Nishimura Y; Nakagawa K; Yamamoto N
BMC Cancer; 2021 Oct; 21(1):1121. PubMed ID: 34663250
[TBL] [Abstract][Full Text] [Related]
8. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
[TBL] [Abstract][Full Text] [Related]
9. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study.
Hendriks LE; Derks JL; Postmus PE; Damhuis RA; Houben RM; Troost EG; Hochstenbag MM; Smit EF; Dingemans AM
Eur J Cancer; 2015 Nov; 51(17):2534-44. PubMed ID: 26323530
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
11. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
Arrieta O; Barrón F; Maldonado F; Cabrera L; Corona-Cruz JF; Blake M; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; García O; Arén O; De la Garza J
Lung Cancer; 2019 Apr; 130():67-75. PubMed ID: 30885354
[TBL] [Abstract][Full Text] [Related]
12. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
13. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Juan O; Popat S
Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
[TBL] [Abstract][Full Text] [Related]
14. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival.
Gray PJ; Mak RH; Yeap BY; Cryer SK; Pinnell NE; Christianson LW; Sher DJ; Arvold ND; Baldini EH; Chen AB; Kozono DE; Swanson SJ; Jackman DM; Alexander BM
Lung Cancer; 2014 Aug; 85(2):239-44. PubMed ID: 24974152
[TBL] [Abstract][Full Text] [Related]
15. Long-term Survival with 18-Fluorodeoxyglucose Positron Emission Tomography-directed Therapy in Non-small Cell Lung Cancer with Synchronous Solitary Brain Metastasis.
Newman S; Bucknell N; Bressel M; Tran P; Campbell BA; David S; Haghighi N; Hanna GG; Kok D; MacManus M; Phillips C; Plumridge N; Shaw M; Wirth A; Wheeler G; Ball D; Siva S
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):163-171. PubMed ID: 33129655
[TBL] [Abstract][Full Text] [Related]
16. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer.
Reddy JP; Tang C; Shih T; Kim B; Kim C; Nguyen QN; Welsh J; Benveniste M; Zhang J; Liao Z; Gomez DR
Clin Lung Cancer; 2017 Mar; 18(2):141-148. PubMed ID: 27913215
[TBL] [Abstract][Full Text] [Related]
17. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
19. Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC.
Badellino S; Levis M; Cuffini EM; Cerrato M; Orlandi E; Chiovatero I; Aprile A; Gastino A; Cavallin C; Iorio GC; Parise R; Mantovani C; Ricardi U
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326616
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
